Rating Change
TD Cowen reiterated its Buy rating on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) on November 05, 2026.
reiterateNASDAQ:ARQT
TD Cowen Reiterates Buy Rating on Arcutis Biotherapeutics, Inc. (ARQT)
TD Cowen reiterated its Buy rating on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) on November 05, 2026.
At publication ·
What changed
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) · reiterate
- Firm
- TD Cowen
- Rating
- Buy to Buy
- Price at event
- $27.00
- Market capitalization
- $3.3B
At a glance
Key takeaways
- TD Cowen reiterated a Buy rating on Arcutis Biotherapeutics (ARQT) on November 5, 2026, with the stock trading at $27.00 and a market cap of $3.3 billion.
Market Context
Arcutis Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $27.00 with a market capitalization of $3.3B.
Analyst coverage from TD Cowen provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Arcutis Biotherapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Arcutis Biotherapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 05, 2026 | TD Cowen | Buy | N/A |
| Oct 19, 2026 | Guggenheim | Buy | N/A |
| Oct 15, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Aug 06, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 06, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ARQT Stock Page
Frequently Asked Questions
What does the Buy rating mean for ARQT?
A rating of Buy from TD Cowen reflects the analyst's outlook on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ARQT forecast page.